How gluten affects gut damage and healing in celiac disease
Studies gluten, gut cells and immunity in adults with celiac disease.
Key facts
- Who runs it
- University of Chicago
- Where
- Chicago, Pasadena, and Rochester, United StatesSee the 3 sites
- Trial code
- Registry title
- Tissue Destruction and Healing in Celiac Disease
- Status
- Recruiting
- People taking part
- 220 people, planned
- Started
- 14 Jul 2023
- Expected to end
- 1 Jul 2027
- Type of study
- Interventional, 3 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Gluten containing snack bar
- Record updated
- 28 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with celiac disease, adults with typical celiac symptoms who still eat gluten, and people without celiac disease as a control group.
- Age
- 18 to 75 years old.
- Sex
- All sexes can join. In the control group, only females who are not pregnant are listed.
- Disease stage
- Gluten challenge group: celiac disease diagnosed by intestinal biopsy for at least 12 months. Gluten de-challenge group: typical celiac disease symptoms. Control group: no history or symptoms of celiac disease.
- Earlier treatment
- Gluten challenge group: a strict gluten-free diet for at least the 12 consecutive months. Gluten de-challenge group: not on a gluten-free diet.
Main reasons for not taking part
- Severe complications of celiac disease, or other chronic or inflammatory gut disease
- Selective IgA deficiency or a severe reaction to gluten
- Blood clotting disorders, or other clinically significant diseases
- Serious substance or alcohol abuse in the past
- Pregnant or breastfeeding (gluten challenge group); for controls: past gut surgery, family history of celiac disease, or taking antibiotics, proton pump inhibitors, aspirin, NSAIDs, antiplatelet agents or anticoagulants
The registry criteria, word for word
Show all 29 criteriaShow less
Who can take part
- Gluten challenge group:
- Age 18 to 75 years old
- Diagnosis of Celiac disease for at least 12 months by intestinal biopsy
- Follow a strict gluten-free diet for at least the 12 consecutive months; Gluten de-challenge group:
- Age 18 to 75 years old
- Showing typical celiac disease symptoms
- Not on a gluten-free diet; Control group:
- Age 18 to 75 years old
- Females who are not pregnant
Who cannot take part
- Gastrointestinal illness within the 4-week period prior to screening
- Taking antibiotics, proton pump inhibitors, aspirin, or non-steroidal anti-inflammatory drugs
- Prior gastrointestinal surgery
- Diagnosis of any severe complication of celiac disease
- Diagnosis of other chronic, active GI disease
- Any clinically significant diseases
- History of significant substance or alcohol abuse
- Diagnosis of blood clotting disorders; Gluten de-challenge group:
- History of chronic inflammatory gastrointestinal disease
- History of lymphoproliferative disease
- Uncontrolled blood clotting disorders
- Any clinically significant diseases
- History of significant substance or alcohol abuse; Control group:
- Family history of celiac disease
- Gluten challenge group:
- Selective IgA deficiency
- Severe reaction to gluten exposure
- Pregnant or lactating
- Known intestinal inflammation
- Taking of antiplatelet agents or anticoagulants
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
- The University Of ChicagoChicago, United StatesContact: Bana Jabri, MDTaking people
- California Institute of TechnologyPasadena, United StatesContact: Rustem Ismagilov, PhDNot yet recruiting
- Mayo ClinicRochester, United StatesContact: Joseph Murray, MDTaking people
About the trial
What the trial wants to find out
The purpose of this clinical study is to learn more about celiac disease pathogenesis and clinical symptoms. In particular, this study will examine the interactions between biological factors such as, intestinal epithelial cells, microbiota, immune system, genetics, and gluten and their effect on celiac disease clinical symptoms, and severity of tissue destruction and its ability to heal in individuals with celiac disease. Information collected in the study will help researchers to generate better resources to advance celiac disease patient care.
The 3 groups in the trial
- Gluten challenge groupTreatment being tested
Diagnosis of celiac disease by intestinal biopsy and serology for at least 12 months
Treatment: Gluten containing snack bar
- Gluten de-challenge groupNo study treatment, for comparison
Suspected celiac disease either showing typical symptoms or positive celiac disease serology
- Control groupNo study treatment, for comparison
No history or symptoms of celiac disease
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Tissue Destruction and Healing in Celiac Disease
- Plain-language title
- How gluten affects gut damage and healing in celiac diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT05680012, who can take part
- Record updated
- 28 July 2026